ObjectiveTo investigate the effect of pramipexole combined with high frequency repetitive transcranial magnetic stimulation (rTMS) in the treatment of Parkinson dementia and the effect on cognitive function and serum CRP and PARK7 in patients. Methods114 cases of Parkinson′s dementia who treated in our hospital from February 2014 to June 2017 were selected. They were divided into observation group and control group by random number table. The control group were treated with pramipexole hydrochloride, and the observation group was treated with high frequency repetitive transcranial magnetic stimulation on the basis of the control group′s treatment. The clinical efficacy, cognitive function, serum C reactive protein (CRP) and recombinant human Parkinson disease protein 7 (PARK7) level were compared between the two groups. ResultsThe total effective rate of treatment in the observation group (94.74%) was significantly higher than that of the control group (75.44%), and the clinical effect was significantly better than that of the control group, with a significant difference (P＜0.05). After 6 weeks of treatment, the MoCA score and the MMSE score of the two groups were significantly higher than those before treatment. The MoCA score and the MMSE score of the patients in the observation group were significantly higher than those in the control group (P＜0.05). After treatment, the serum CRP and PARK7 levels of the two groups were significantly lower than those before treatment. The serum levels of CRP and PARK7 in the observation group were significantly lower than those in the control group, the difference was statistically significant (P＜0.05). ConclusionPramipexole hydrochloride combined with rTMS can effectively improve the clinical therapeutic effect, improve cognitive function and reduce serum CRP and PARK7 levels in patients with Parkinson′s dementia.

无